| 翻訳と辞書 |
Idelalisib
Idelalisib (trade name Zydelig, codenamed GS-1101 or CAL-101) is a drug used for the treatment of chronic lymphocytic leukemia. The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.〔〔
==Medical uses==
Idelalisib is a second line drug for patients whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab,〔 idelalisib is to be used in patients for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions.〔 It appears to be very effective drug and leads to rapid resolution of lymphadenopathy and splenomegaly. However, the lymphocyte counts takes longer to decrease to normal levels with idelalisib. Idelalisib is effective in patients who have a p53 mutation, which otherwise tends to impart a poor prognosis in CLL patients. This is important as even the first line chemotherapy regimens, such as those incorporating fludarabine are ineffective in patients with p53 mutation. It is also being studied in clinical trials for first line treatment in high risk CLL patients, who are otherwise unable to tolerate aggressive chemotherapy due to their medical history or age.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Idelalisib」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|